Sakubitril + valsartan
Sakubitril + valsartan
Klass : 3
Visa all info
Skriv ut
Kontakta oss
EMA. Entresto. Public Assessment Report 2015-09-24. http://goo.gl/keOF6Q
Barr M. Teratogen update: angiotensin-converting enzyme inhibitors. Teratology 1994;50:399-409.
Weber-Schoendorfer C, Kayser A, Tissen-Diabaté T, Winterfeld U, Eleftheriou G, Te Winkel B et al. Fetotoxic risk of AT1 blockers exceeds that of angiotensin-converting enzyme inhibitors: an observational study. J Hypertens. 2020;38(1):133-141.
Shimada C, Akaishi R, Cho K, Morikawa M, Kaneshi Y, Yamda T et al. Outcomes of 83 fetuses exposed to angiotensin receptor blockers during the second or third trimesters: a literature review. Hypertens Res. 2015;38(5):308-13.
Alwan S, Polifka JE, Friedman JM. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol 2005;73:123-30.
- EMA. Entresto. Public Assessment Report 2015-09-24. http://goo.gl/keOF6Q
- Barr M. Teratogen update: angiotensin-converting enzyme inhibitors. Teratology 1994;50:399-409.
- Weber-Schoendorfer C, Kayser A, Tissen-Diabaté T, Winterfeld U, Eleftheriou G, Te Winkel B et al. Fetotoxic risk of AT1 blockers exceeds that of angiotensin-converting enzyme inhibitors: an observational study. J Hypertens. 2020;38(1):133-141.
- Shimada C, Akaishi R, Cho K, Morikawa M, Kaneshi Y, Yamda T et al. Outcomes of 83 fetuses exposed to angiotensin receptor blockers during the second or third trimesters: a literature review. Hypertens Res. 2015;38(5):308-13.
- Alwan S, Polifka JE, Friedman JM. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol 2005;73:123-30.